Centrexion stock hits 52-week low at $0.79 amid market challenges

Published 11/02/2025, 19:56
Centrexion stock hits 52-week low at $0.79 amid market challenges

In a turbulent market environment, Centrexion Therapeutics Corp (CNTX) stock has touched a new 52-week low, with shares falling to $0.79. According to InvestingPro data, this represents a stark contrast from the stock’s 52-week high of $2.75, with the company now valued at approximately $75 million. This latest price level reflects a significant downturn for the biopharmaceutical company, which has experienced a 1-year change with a decline of -29.82%. Investors are closely monitoring Centrexion as it navigates through a challenging phase, marked by this notable dip in its stock price. The company, which focuses on developing treatments for chronic pain and inflammation, is now grappling with market dynamics that have pushed its shares to the lowest point in the past year. Despite current challenges, InvestingPro analysis shows the company maintains a strong liquidity position with a current ratio of 36.91, and analysts have set price targets ranging from $4 to $10. InvestingPro subscribers can access 10+ additional insights about CNTX’s financial health and market position.

In other recent news, Context Therapeutics has announced the appointment of Andy Pasternak as the new Chairman of the Board of Directors. Pasternak, who brings over 25 years of biopharmaceutical experience, succeeds Richard Berman. Notably, Pasternak played a significant role in the $28 billion acquisition of Horizon Therapeutics (NASDAQ:HZNP) by Amgen (NASDAQ:AMGN), Inc. in 2023.

In addition to the leadership transition, JMP Securities initiated coverage on Context Therapeutics with a Market Outperform rating. The firm’s confidence in the company’s approach to cancer treatment is reflected in the $4 price target derived from a Discounted Cash Flow analysis.

Among the recent developments, Context Therapeutics is actively developing a portfolio of bispecific antibodies, including CTIM-76, CT-95, and CT-202. These therapies are designed to target specific antigens implicated in solid tumor pathologies, aiming to improve the safety and effectiveness of the treatments.

These recent developments indicate Context Therapeutics’ continued commitment to its mission in the biopharmaceutical industry, with Pasternak’s extensive background expected to guide the company into its next phase of growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.